MARATTO

article · Minia Journal of Medical Research

Role Of platelet-Rich Plasma in Treatment of Post COVID-19 Olfactory Dysfunction

2024Open accessMinia University

Abstract

Background: COVID-19-related olfactory dysfunction is a serious problem that affect quality of life. With Limited effective therapies exist we discuss the role of platelet-Rich Plasma as a therapeutic agent for this problem.Aim of the study: Evaluation of effect of platelet-rich plasma in treatment of Post COVID-19 Olfactory DysfunctionPatients and methods: The study recruited 28 patients with Post COVID-19 olfactory Dysfunction (Anosmia / hyposmia / Cacosmia) From E.N.T outpatient clinic of Minya university hospital. patients received platelet-rich plasma only in form of injection in olfactory cleft.Results: The median of Butanol Threshold test before for patients was 3 (1.5 – 4) , The median of Butanol Threshold test after for patients was 3 (1.5 – 5) , There was highly statistically significant increase among butanol threshold test after treatment than butanol threshold test before treatment. Conclusions: In conclusion, our findings indicated that using of PRP significantly reduced the duration of anosmia in patients. Notably, A highly statistically significant increase in Butanol Threshold tests after treatment compared to before, underscoring the potential benefit of PRP in addressing olfactory dysfunction in Post COVID-19 patients.

Research topics

  • Vagus Nerve Stimulation Research
  • Olfactory and Sensory Function Studies

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/mjmr.2024.255026.1563

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.